Data as of Dec 05
| +0.11 / +0.28%|
The 6 analysts offering 12-month price forecasts for KYTHERA Biopharmaceuticals Inc have a median target of 53.50, with a high estimate of 60.00 and a low estimate of 42.00. The median estimate represents a +34.63% increase from the last price of 39.74.
The current consensus among 6 polled investment analysts is to Buy stock in KYTHERA Biopharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.